COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

31,822 Articles (22,968 medRxiv, 8,854 bioRxiv)

Most recent first Previous |  Page 3105: Articles 31041-31050  | Next

Risk Factors Associated with Clinical Outcomes in 323 COVID-19 Patients in Wuhan, China
Hu, L., Chen, S., Fu, Y., Gao, Z., Long, H., Ren, H.-w., Zuo, Y., Li, H., Wang, J., Xv, Q.-b., Yu, W.-x., Liu, J., Shao, C., Hao, J.-j., Wang, C.-z., Ma, Y., Wang, Z., Yanagihara, R., Wang, J.-m., Deng, Y.
10.1101/2020.03.25.20037721 — Posted: 2020-03-26
A Fully Automatic Deep Learning System for COVID-19 Diagnostic and Prognostic Analysis
Wang, S., Zha, Y., Li, W., Wu, Q., Li, X., Niu, M., Wang, M., Qiu, X., Li, H., Yu, H., Gong, W., Bai, Y., Li, L., Zhu, Y., Wang, L., Tian, J.
10.1101/2020.03.24.20042317 — Posted: 2020-03-26
Human Mobility Restrictions and the Spread of the Novel Coronavirus (2019-nCoV) in China
FANG, H., WANG, L., YANG, Y.
10.1101/2020.03.24.20042424 — Posted: 2020-03-26
The potential SARS-CoV-2 entry inhibitor
Lung, J., Lin, Y.-S., Yang, Y.-H., Chou, Y.-L., Chang, G.-H., Tsai, M.-S., Hsu, C.-M., Yeh, R.-A., Shu, L.-H., Cheng, Y.-C., Te Liu, H., Wu, C.-Y.
10.1101/2020.03.26.009803 — Posted: 2020-03-26
An artificial intelligence based first-line defence against COVID-19: digitally screeningcitizens for risks via a chatbot
Martin, A., Nateqi, J., Gruarin, S., Munsch, N., Abdarahmane, I., Knapp, B.
10.1101/2020.03.25.008805 — Posted: 2020-03-26
Estimating the maximum daily number of incident COVID-19 cases manageable by a healthcare system
Giannakeas, V., Bhatia, D., Warkentin, M. T., Bogoch, I., Stall, N. M.
10.1101/2020.03.25.20043711 — Posted: 2020-03-25
An international comparison of the second derivative of COVID-19 deaths after implementation of social distancing measures
Pike, W. T., Saini, V.
10.1101/2020.03.25.20041475 — Posted: 2020-03-25 Discussion: Onsite
scRNA-seq reveals ACE2 and TMPRSS2 expression in TROP2+ Liver Progenitor Cells: Implications in COVID-19 associated Liver Dysfunction
Seow, J. J. W., Pai, R., Mishra, A., Shepherdson, E., Lim, T. K. H., Goh, B. K. P., Chan, J. K., Chow, P. K., Ginhoux, F., DasGupta, R., Sharma, A.
10.1101/2020.03.23.002832 — Posted: 2020-03-25 Discussion: Onsite
Analysis of Serologic Cross-Reactivity Between Common Human Coronaviruses and SARS-CoV-2 Using Coronavirus Antigen Microarray
Khan, S., Nakajima, R., Jain, A., de Assis, R. R., Jasinskas, A., Obiero, J. M., Adenaiye, O., Tai, S., Hong, F., Milton, D. K., Davies, H., Felgner, P. L., Prometheus Study Group
10.1101/2020.03.24.006544 — Posted: 2020-03-25 Discussion: Onsite
FEP-based screening prompts drug repositioning against COVID-19
Li, Z., Li, X., Huang, Y.-Y., Wu, Y., Zhou, L., Liu, R., Wu, D., Zhang, L., Liu, H., Xu, X., Zhang, Y., Cui, J., Wang, X., Luo, H.-B.
10.1101/2020.03.23.004580 — Posted: 2020-03-25 Discussion: Onsite

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).